Abstract: In vitro survival measurements using two human head-and-neck cancer (HNC) cell lines were performed. The specially designed split-dose surviving fraction was obtained and fitted to the linear-quadratic formalism. The repair halftime (Tr), the potential doubling time (Td), a/β and radiosensitivity a, were estimated. Other radiobiological models: EUD, BED, TCP, etc., were used to examine the potential treatment effectiveness of different IMRT techniques. Our data indicated the repair halftime of ~17 min based on two HNC cell lines. The combined a/β, a and Td are a/β = 8.1 ± 4.1 Gy, a = 0.22 ± 0.08 Gy−1, Td = 4.0 ± 1.8 day, respectively. The prolonged IMRT dose delivery for entire HNC treatment course could possibly result in the loss of biological effectiveness, i.e., the target EUDs decreased by 11% with fraction dose delivery time varying from 5 to 30 min. We determined the sublethal damage repair halftime and other radiobiological parameters for HNC cells, and to evaluate treatment effectiveness of the prolonged dose delivery times associated with different IMRT techniques. The estimated repair halftime for HNC is relatively short and may be comparable to the step-and-shoot IMRT fraction dose delivery time. The effectiveness of IMRT treatment may be improved by reducing the fraction delivery time for HNC treatment.
Keywords: head-and-neck cancer; linear-quadratic model; sublethal damage repair halftime; fraction dose delivery time; intensity modulated radiation therapy
Export to BibTeX
MDPI and ACS Style
Qi, X.S.; Yang, Q.; Lee, S.P.; Li, X.A.; Wang, D. An Estimation of Radiobiological Parameters for Head-and-Neck Cancer Cells and the Clinical Implications. Cancers 2012, 4, 566-580.
Qi XS, Yang Q, Lee SP, Li XA, Wang D. An Estimation of Radiobiological Parameters for Head-and-Neck Cancer Cells and the Clinical Implications. Cancers. 2012; 4(2):566-580.
Qi, X. Sharon; Yang, Qiuhui; Lee, Steve P.; Li, X. Allen; Wang, Dian. 2012. "An Estimation of Radiobiological Parameters for Head-and-Neck Cancer Cells and the Clinical Implications." Cancers 4, no. 2: 566-580.